Every 10-Q that Cel-Sci Corporation (CVM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVM filings page.
CEL-SCI Corporation reported continued operating losses and tight liquidity for the nine months ended June 30, 2026 while advancing its cancer immunotherapy program Multikine toward a planned confirmatory Phase 3 registration study. The company generated no revenue and recorded a net loss of $16.6 million, modestly improved from $19.3 million a year earlier, driven by lower research and development and general and administrative expenses.
Total assets declined to $21.4 million from $28.2 million, with cash and cash equivalents falling to $6.5 million from $11.0 million. Net cash used in operating activities was $12.1 million, partly offset by $9.7 million of equity financing proceeds and officer purchases, resulting in a $4.4 million cash decrease. Stockholders’ equity fell to $11.0 million from $16.0 million, and the accumulated deficit widened to $556.0 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and future liquidity needs. To fund a 212‑patient Multikine confirmatory registration study, the cost is estimated at $30–$35 million, and additional financing through partnerships, debt, or equity will be required.
CEL-SCI Corporation reported another loss-making quarter as it advances its lead cancer immunotherapy, Multikine, toward a planned Phase 3 confirmatory registration study. For the six months ended March 31, 2026, the company posted a net loss of about $10.9 million, improving from $13.6 million a year earlier as both research and development and general and administrative expenses declined.
Cash and cash equivalents fell sharply to $1.9 million from $11.0 million at September 30, 2025, while total assets dropped to $17.7 million. Management discloses “substantial doubt” about CEL-SCI’s ability to continue as a going concern and estimates the planned confirmatory Multikine study will cost roughly $30–$35 million, requiring additional financing.
The company highlights Phase 3 data in a defined head and neck cancer target population, where it reports a 5‑year survival rate of 73% with Multikine versus 45% without, and a hazard ratio of 0.35, and is preparing global regulatory filings while relying heavily on future equity or partnership funding to sustain operations.
CEL-SCI Corporation reported another loss-making quarter and reiterated serious liquidity risks. For the three months ended December 31, 2025, the company recorded a net loss of about $5.5 million, an improvement from $7.1 million a year earlier, as both research and development and general and administrative expenses declined.
Cash and cash equivalents fell to roughly $6.3 million from $11.0 million at September 30, 2025, driven mainly by operating cash outflows and lease payments. CEL-SCI has generated no product revenue and discloses “substantial doubt” about its ability to continue as a going concern without new financing.
The company remains focused on its lead cancer immunotherapy, Multikine, which in a prior Phase III study showed a five‑year survival rate of 73% in a defined head and neck cancer target population versus 45% in controls and a hazard ratio of 0.35. CEL-SCI plans a 212‑patient confirmatory registration study, estimated to cost $30–$35 million, and states that starting this trial depends on raising additional capital.
Cel‑Sci Corporation (CVM) reported unaudited results for the quarterly period ended June 30, 2025. Total assets were $20.34 million versus $26.99 million a year earlier, driven by a cash decline to $1.79 million from $4.74 million. The company recorded a nine‑month net loss of $19.31 million compared to $20.81 million in the prior year; research and development expense was $12.18 million and general and administrative expense was $6.59 million. Cash used in operating activities totaled $12.45 million while proceeds from issuance of common stock and pre‑funded warrants were $12.56 million during the period. Management discloses substantial doubt about the company’s ability to continue as a going concern and estimates about $30 million will be required to finance the planned 212‑patient confirmatory Multikine study. A 30‑for‑1 reverse stock split became effective in May 2025 and shares outstanding were 5,321,341 at June 30, 2025. Subsequent to period end the company sold 1,500,000 shares for approximately $5.7 million.